Its unethical because it risks mosaicism and off target effects
Melanie Hess -2020 A Call for an International Governance Framework for Human Germline Gene Editing 95 Notre Dame Law Review 1369 https://scholarship.law.nd.edu/cgi/viewcontent.cgi?article=4899&context=ndlr
Legal professor and bioethicist Katherine Drabiak describes the rhetoric around gene editing “intentionally misleading,” stating that the current state of technology is not as efficient as it is believed to be in terms of its potential benefits, and that, in fact, there is significant risk involved.47 The medical risks associated with germline gene editing include mosaicism, meaning some genes contain the intended modification and others do not. This can lead to serious health risks in later stages of development48 and other off target effects. Off-target effects “refer to a range of unintended outcomes” that can have serious health impacts on the child, including advanced aging or the development of tumors.49 Problematically, preimplantation genetic diagnosis (PGD), a process used to test the health of an embryo prior to implantation for pregnancy,50 often fails to accurately assess the effects of gene editing on an embryo. The inability to use PGD to test the health of an edited embryo would make it difficult to ascertain the germline editing procedure’s effectiveness prior to the embryo’s implantation. In other words, PGD cannot be used as a safeguard to indicate whether the editing has worked correctly prior to implantation.51 PGD can, however, be used to assess whether a defective gene is present in an unedited embryo, which is why Drabiak points to this as a better alternative to germline editing.52 Finally, there are a range of unpredictable effects that may emerge at any point in the future person’s life as a result of tampering with their initial germline cells. Drabiak notes that current research touting effectiveness incorrectly presumes that, following a gene editing procedure, “embryo survival equates to health.”53 In other words, a test subject embryo’s surviving the trial is not necessarily an indication of how the fetus will fare in the next nine months, or the years and decades following its birth. Some scholars believe that “germline modification will never be safe . . . because interactions between genes are highly integrated, designed to achieve stability and balance, and manipulation of one location risks disrupting the biological equilibrium.”54 Of course, this poses a serious obstacle to any research: with the current expert consensus on a moratorium on any applications that would result in a pregnancy,55 it is not possible to observe effects of germline editing on later stages of development of a child. Drabiak proposes that these risks are severe enough that they easily outweigh any benefits that germline gene editing could ever theoretically provide.56